In un bulletin published on May 16, 2024, the National Agency for the Safety of Medicines and Health Products (ANSM) issues a “health policy” decision in order toprevent the exploitation and promotion of the ImuPatch product from the company Sodeval, deemed to be at risk due to its lack of official validation by the health authorities.
This sanction follows the promotion of this patch “on the company’s website, its social networks and sending mass mailings” Or the ImuPatch product was presented as having virtues “revolutionary preventive and curative measures for health”without these having been scientifically demonstrated and validated by the health authorities.
ImuPatch: why is this product considered risky by the ANSM?
The ImuPatch patch from the company Sodeval is composed of Valentonin and 6-Methoxy-Harmalan and presented in these advertisements pinned by the ANSM as a set of “revolutionary preventive and curative treatments for health, advanced therapeutic solutions and practical alternatives to traditional treatments”, particularly against cancer, Alzheimer’s disease, Parkinsonthe multiple sclerosisor with AIDS.
However, the ANSM recalls that this product has not been the subject of any prior marketing authorization, nor a visa for advertising provided for by the Public Health Code. Furthermore, the agency adds that the patients targeted by this product suffer from serious pathologies, who may be more vulnerable because of their state of health, must be taken care of by “proven treatments, the benefits and risks of which have been evaluated by health authorities”. Concerning the ImuPatch product, the ANSM is clear, “the lack of guarantee as to the origin, quality, effectiveness and safety of this patch outside the pharmaceutical circuit represents health risks”. This is why the agency took the decision to suspend the advertising and exploitation of the ImuPatch product by the company Sodeval, “until it has been brought into compliance with the regulations applicable to it”.
The Sodeval company is not its first call to order
The company Sodeval, responsible for the ImuPatch product, is not its first prank. Indeed, she was the subject of legal proceedings for having organized an unauthorized clinical trial in 2019 on more than 350 vulnerable people to whom Valentonin and 6-Methoxy-Harmalan were administered via a patch not validated by the health authorities. The president of the Sodeval company, Jean-Bernard Fourtillan, was also indicted in March 2020 for illegal exercise of the profession of pharmacist.
Source :
- The ANSM suspends the advertising and operation of ImuPatch transdermal patches from the company Sodeval – ANSM – May 16, 2024
